Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold
The US FDA appears to have concerns about the device used to administer the vaccine.
You may also be interested in...
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.